Quidel Corporation (NASDAQ:QDEL) SVP Michael Donald Jr. Abney sold 1,173 shares of the firm’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $33.83, for a total transaction of $39,682.59. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Quidel Corporation (QDEL) traded up 0.43% during trading on Friday, reaching $32.61. The company’s stock had a trading volume of 132,775 shares. The firm’s market cap is $1.09 billion. The stock’s 50 day moving average is $32.13 and its 200 day moving average is $25.45. Quidel Corporation has a one year low of $18.25 and a one year high of $38.92.
Quidel Corporation (NASDAQ:QDEL) last issued its quarterly earnings results on Wednesday, July 26th. The company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.18. The firm had revenue of $38.30 million during the quarter, compared to analysts’ expectations of $41.91 million. Quidel Corporation had a negative return on equity of 0.03% and a negative net margin of 0.03%. Quidel Corporation’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.11) earnings per share. On average, equities analysts forecast that Quidel Corporation will post $0.28 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Quidel Corporation (QDEL) SVP Sells $39,682.59 in Stock” was originally published by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://rinconhillneighbors.org/2017/08/19/michael-donald-jr-abney-sells-1173-shares-of-quidel-corporation-qdel-stock-updated-updated.html.
Several large investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its stake in Quidel Corporation by 42.2% in the second quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock worth $100,000 after buying an additional 1,091 shares in the last quarter. First Mercantile Trust Co. boosted its stake in Quidel Corporation by 0.8% in the first quarter. First Mercantile Trust Co. now owns 5,280 shares of the company’s stock worth $120,000 after buying an additional 40 shares in the last quarter. Legal & General Group Plc boosted its stake in Quidel Corporation by 4.6% in the first quarter. Legal & General Group Plc now owns 6,931 shares of the company’s stock worth $157,000 after buying an additional 306 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Quidel Corporation during the second quarter worth approximately $209,000. Finally, First Quadrant L P CA bought a new stake in Quidel Corporation during the second quarter worth approximately $217,000. 89.66% of the stock is currently owned by hedge funds and other institutional investors.
QDEL has been the subject of several research reports. Zacks Investment Research downgraded shares of Quidel Corporation from a “hold” rating to a “strong sell” rating in a research report on Saturday, July 29th. BidaskClub downgraded shares of Quidel Corporation from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 16th. William Blair raised shares of Quidel Corporation from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 18th. TheStreet downgraded shares of Quidel Corporation from a “b-” rating to a “c” rating in a research report on Wednesday, July 26th. Finally, Barclays PLC lifted their price target on shares of Quidel Corporation from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, April 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Quidel Corporation currently has an average rating of “Hold” and an average target price of $31.40.
Quidel Corporation Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with our FREE daily email newsletter.